News & Press
Members of Access to Comprehensive Genomic Profiling (ACGP) Participated in Precision Medicine Leadership Summit’s Virtual Series on Genomics and Precision Medicine
On April 27, 2021, members of the Access to Comprehensive Genomic Profiling (ACGP) participated in the Precision Medicine Leadership Summit’s Virtual Series on Genomics and Precision Medicine. Lauren Feldman, Vice President, Value, Access & Pricing at ADVI, moderated the panel “Comprehensive Genomic Profiling: A New Standard of Care in Oncology”, which covered:
- The landscape for comprehensive genomic profiling
- The obstacles to coverage & reimbursement
- Access to Comprehensive Genomic Profiling Coalition
The panelists were as follows: Mina Alsaraf Allo, PharmD, MPH, VP, Commercial Markets – East, Tempus, Trish Brown, MS, Director, AMR Payer Partner, Field Market Access Lead, Illumina, and Rob Dumanois, Director, Reimbursement Strategy, Thermo Fisher Scientific.
Access to Comprehensive Genomic Profiling (ACGP) is a collaborative coalition of leading molecular diagnostics companies and laboratories that aims to raise awareness about comprehensive genomic profiling (CGP) for advanced cancer patients. For more information, please visit: https://accesstocgp.com/
AstraZeneca, Loxo Oncology at Lilly, and Invitae Corporation Join the Access to Comprehensive Genomic Profiling Coalition
WASHINGTON, April 19, 2021 /PRNewswire/ — The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of AstraZeneca, Loxo Oncology at Lilly, and Invitae Corporation (NYSE: NVTA) to its coalition of companies advocating for appropriate coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer by U.S. health insurers.
NeoGenomics and Tempus Join the Access to Comprehensive Genomic Profiling Coalition
The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of NeoGenomics, Inc. (NASDAQ: NEO) and Tempus to its coalition of diagnostics companies and laboratory service providers to advocate for appropriate broad U.S. health insurance coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer.
Leading Diagnostics Companies Join Forces to Establish the Access to Comprehensive Genomic Profiling Coalition (ACGP)
Consortium aims to make comprehensive genomic profiling accessible to advanced cancer patients in the U.S. to inform medical management and improve patient outcomes.
WASHINGTON, Nov. 17, 2020 /PRNewswire/ — Seven leading diagnostics companies and laboratory service providers have formed the Access to Comprehensive Genomic Profiling Coalition (ACGP). The goal of the organization is to collectively advocate for appropriate broad U.S. health insurance coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer. The current members of ACGP are Exact Sciences (NASDAQ: EXAS), Foundation Medicine, Illumina (NASDAQ: ILMN), LabCorp (NYSE: LH), QIAGEN (NYSE: QGEN), Roche Diagnostics (SIX: RO, ROG:OTCQX: RHHBY), and Thermo Fisher Scientific (NYSE: TMO).